-
1
-
-
20944448555
-
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial
-
[1] Gilman, S., Koller, M., Black, R.S., Jenkins, L., Griffith, S.G., Fox, N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005), 1553–1562.
-
(2005)
Neurology
, vol.64
, pp. 1553-1562
-
-
Gilman, S.1
Koller, M.2
Black, R.S.3
Jenkins, L.4
Griffith, S.G.5
Fox, N.C.6
-
2
-
-
10744230547
-
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization
-
[2] Orgogozo, J.M., Gilman, S., Dartigues, J.F., Laurent, B., Puel, M., Kirby, L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003), 46–54.
-
(2003)
Neurology
, vol.61
, pp. 46-54
-
-
Orgogozo, J.M.1
Gilman, S.2
Dartigues, J.F.3
Laurent, B.4
Puel, M.5
Kirby, L.C.6
-
3
-
-
0037384333
-
Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid
-
[3] Cribbs, D.H., Ghochikyan, A., Vasilevko, V., Tran, M., Petrushina, I., Sadzikava, N., et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15 (2003), 505–514.
-
(2003)
Int Immunol
, vol.15
, pp. 505-514
-
-
Cribbs, D.H.1
Ghochikyan, A.2
Vasilevko, V.3
Tran, M.4
Petrushina, I.5
Sadzikava, N.6
-
4
-
-
77953282150
-
A single ascending dose study of bapineuzumab in patients with Alzheimer disease
-
[4] Black, R.S., Sperling, R.A., Safirstein, B., Motter, R.N., Pallay, A., Nichols, A., et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 24 (2010), 198–203.
-
(2010)
Alzheimer Dis Assoc Disord
, vol.24
, pp. 198-203
-
-
Black, R.S.1
Sperling, R.A.2
Safirstein, B.3
Motter, R.N.4
Pallay, A.5
Nichols, A.6
-
5
-
-
77951086901
-
Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
-
[5] Siemers, E.R., Friedrich, S., Dean, R.A., Gonzales, C.R., Farlow, M.R., Paul, S.M., et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33 (2010), 67–73.
-
(2010)
Clin Neuropharmacol
, vol.33
, pp. 67-73
-
-
Siemers, E.R.1
Friedrich, S.2
Dean, R.A.3
Gonzales, C.R.4
Farlow, M.R.5
Paul, S.M.6
-
6
-
-
84893295027
-
Active immunotherapy options for Alzheimer's disease
-
[6] Winblad, B., Graf, A., Riviere, M.E., Andreasen, N., Ryan, J.M., Active immunotherapy options for Alzheimer's disease. Alzheimers Res Ther, 6, 2014, 7.
-
(2014)
Alzheimers Res Ther
, vol.6
, pp. 7
-
-
Winblad, B.1
Graf, A.2
Riviere, M.E.3
Andreasen, N.4
Ryan, J.M.5
-
7
-
-
84892695519
-
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease
-
[7] Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 322–333.
-
(2014)
N Engl J Med
, vol.370
, pp. 322-333
-
-
Salloway, S.1
Sperling, R.2
Fox, N.C.3
Blennow, K.4
Klunk, W.5
Raskind, M.6
-
8
-
-
84892748542
-
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease
-
[8] Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 311–321.
-
(2014)
N Engl J Med
, vol.370
, pp. 311-321
-
-
Doody, R.S.1
Thomas, R.G.2
Farlow, M.3
Iwatsubo, T.4
Vellas, B.5
Joffe, S.6
-
9
-
-
84862331908
-
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
-
[9] Winblad, B., Andreasen, N., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11 (2012), 597–604.
-
(2012)
Lancet Neurol
, vol.11
, pp. 597-604
-
-
Winblad, B.1
Andreasen, N.2
Minthon, L.3
Floesser, A.4
Imbert, G.5
Dumortier, T.6
-
10
-
-
79959670013
-
The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects
-
[10] Wiessner, C., Wiederhold, K.H., Tissot, A.C., Frey, P., Danner, S., Jacobson, L.H., et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 31 (2011), 9323–9331.
-
(2011)
J Neurosci
, vol.31
, pp. 9323-9331
-
-
Wiessner, C.1
Wiederhold, K.H.2
Tissot, A.C.3
Frey, P.4
Danner, S.5
Jacobson, L.H.6
-
11
-
-
84928569750
-
Long-term treatment with active Abeta immunotherapy with CAD106 in mild Alzheimer's disease
-
[11] Farlow, M.R., Andreasen, N., Riviere, M.E., Vostiar, I., Vitaliti, A., Sovago, J., et al. Long-term treatment with active Abeta immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimers Res Ther, 7, 2015, 23.
-
(2015)
Alzheimers Res Ther
, vol.7
, pp. 23
-
-
Farlow, M.R.1
Andreasen, N.2
Riviere, M.E.3
Vostiar, I.4
Vitaliti, A.5
Sovago, J.6
-
12
-
-
10744227803
-
Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells
-
[12] Karlsson, A.C., Martin, J.N., Younger, S.R., Bredt, B.M., Epling, L., Ronquillo, R., et al. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods 283 (2003), 141–153.
-
(2003)
J Immunol Methods
, vol.283
, pp. 141-153
-
-
Karlsson, A.C.1
Martin, J.N.2
Younger, S.R.3
Bredt, B.M.4
Epling, L.5
Ronquillo, R.6
-
13
-
-
84858591462
-
Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects
-
[13] Joshi, A.D., Pontecorvo, M.J., Clark, C.M., Carpenter, A.P., Jennings, D.L., Sadowsky, C.H., et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med 53 (2012), 378–384.
-
(2012)
J Nucl Med
, vol.53
, pp. 378-384
-
-
Joshi, A.D.1
Pontecorvo, M.J.2
Clark, C.M.3
Carpenter, A.P.4
Jennings, D.L.5
Sadowsky, C.H.6
-
14
-
-
0037205207
-
Aluminum salts in vaccines—US perspective
-
[14] Baylor, N.W., Egan, W., Richman, P., Aluminum salts in vaccines—US perspective. Vaccine 20 (2002), S18–S23.
-
(2002)
Vaccine
, vol.20
, pp. S18-S23
-
-
Baylor, N.W.1
Egan, W.2
Richman, P.3
-
15
-
-
18144415471
-
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
-
[15] Fox, N.C., Black, R.S., Gilman, S., Rossor, M.N., Griffith, S.G., Jenkins, L., et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64 (2005), 1563–1572.
-
(2005)
Neurology
, vol.64
, pp. 1563-1572
-
-
Fox, N.C.1
Black, R.S.2
Gilman, S.3
Rossor, M.N.4
Griffith, S.G.5
Jenkins, L.6
|